PUMA BIOTECHNOLOGY INC (PBYI) Stock Fundamental Analysis
USA - NASDAQ:PBYI - US74587V1070 - Common Stock
4.44 USD
-0.03 (-0.67%)
Overall PBYI gets a fundamental rating of 5 out of 10. We evaluated PBYI against 540 industry peers in the Biotechnology industry. PBYI has an excellent profitability rating, but there are some minor concerns on its financial health. PBYI is cheap, but on the other hand it scores bad on growth. These ratings would make PBYI suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year PBYI was profitable.
In the past year PBYI had a positive cash flow from operations.
In multiple years PBYI reported negative net income over the last 5 years.
Of the past 5 years PBYI 4 years had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 24.86%, PBYI belongs to the best of the industry, outperforming 97.59% of the companies in the same industry.
PBYI has a better Return On Equity (46.27%) than 98.52% of its industry peers.
With an excellent Return On Invested Capital value of 31.42%, PBYI belongs to the best of the industry, outperforming 99.07% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for PBYI is above the industry average of 15.95%.
The last Return On Invested Capital (31.42%) for PBYI is above the 3 year average (17.97%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.86% | ||
| ROE | 46.27% | ||
| ROIC | 31.42% |
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
1.3 Margins
PBYI's Profit Margin of 20.35% is amongst the best of the industry. PBYI outperforms 94.44% of its industry peers.
Looking at the Operating Margin, with a value of 19.35%, PBYI belongs to the top of the industry, outperforming 94.26% of the companies in the same industry.
In the last couple of years the Operating Margin of PBYI has grown nicely.
The Gross Margin of PBYI (72.33%) is better than 82.22% of its industry peers.
In the last couple of years the Gross Margin of PBYI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.35% | ||
| PM (TTM) | 20.35% | ||
| GM | 72.33% |
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PBYI is creating value.
Compared to 1 year ago, PBYI has more shares outstanding
The number of shares outstanding for PBYI has been increased compared to 5 years ago.
PBYI has a better debt/assets ratio than last year.
2.2 Solvency
PBYI has an Altman-Z score of -5.53. This is a bad value and indicates that PBYI is not financially healthy and even has some risk of bankruptcy.
PBYI has a worse Altman-Z score (-5.53) than 62.59% of its industry peers.
The Debt to FCF ratio of PBYI is 1.01, which is an excellent value as it means it would take PBYI, only 1.01 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 1.01, PBYI belongs to the best of the industry, outperforming 94.63% of the companies in the same industry.
A Debt/Equity ratio of 0.10 indicates that PBYI is not too dependend on debt financing.
PBYI has a worse Debt to Equity ratio (0.10) than 64.63% of its industry peers.
Although PBYI does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 1.01 | ||
| Altman-Z | -5.53 |
ROIC/WACC2.87
WACC10.94%
2.3 Liquidity
PBYI has a Current Ratio of 1.73. This is a normal value and indicates that PBYI is financially healthy and should not expect problems in meeting its short term obligations.
PBYI's Current ratio of 1.73 is on the low side compared to the rest of the industry. PBYI is outperformed by 78.89% of its industry peers.
A Quick Ratio of 1.62 indicates that PBYI should not have too much problems paying its short term obligations.
PBYI has a worse Quick ratio (1.62) than 79.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.62 |
3. Growth
3.1 Past
PBYI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 415.79%, which is quite impressive.
The Revenue has grown by 8.63% in the past year. This is quite good.
PBYI shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.28% yearly.
EPS 1Y (TTM)415.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%233.33%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%11.25%
3.2 Future
Based on estimates for the next years, PBYI will show a very negative growth in Earnings Per Share. The EPS will decrease by -12.89% on average per year.
The Revenue is expected to decrease by -1.09% on average over the next years.
EPS Next Y-17.31%
EPS Next 2Y-26.51%
EPS Next 3Y-17.16%
EPS Next 5Y-12.89%
Revenue Next Year-3.32%
Revenue Next 2Y-3.85%
Revenue Next 3Y-2.82%
Revenue Next 5Y-1.09%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 4.53 indicates a rather cheap valuation of PBYI.
PBYI's Price/Earnings ratio is rather cheap when compared to the industry. PBYI is cheaper than 97.96% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.30. PBYI is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 13.48, which indicates a correct valuation of PBYI.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PBYI indicates a rather cheap valuation: PBYI is cheaper than 95.37% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of PBYI to the average of the S&P500 Index (22.73), we can say PBYI is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.53 | ||
| Fwd PE | 13.48 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PBYI is valued cheaper than 98.89% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PBYI is valued cheaper than 99.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.06 | ||
| EV/EBITDA | 2.31 |
4.3 Compensation for Growth
PBYI has an outstanding profitability rating, which may justify a higher PE ratio.
PBYI's earnings are expected to decrease with -17.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.51%
EPS Next 3Y-17.16%
5. Dividend
5.1 Amount
No dividends for PBYI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PBYI (9/15/2025, 11:29:01 AM)
4.44
-0.03 (-0.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners66.27%
Inst Owner Change7.37%
Ins Owners15.35%
Ins Owner Change0.07%
Market Cap223.64M
Analysts47.5
Price Target4.42 (-0.45%)
Short Float %6.21%
Short Ratio4.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)204.35%
Min EPS beat(2)14.59%
Max EPS beat(2)394.12%
EPS beat(4)4
Avg EPS beat(4)173.94%
Min EPS beat(4)14.59%
Max EPS beat(4)394.12%
EPS beat(8)7
Avg EPS beat(8)102.62%
EPS beat(12)10
Avg EPS beat(12)105.29%
EPS beat(16)13
Avg EPS beat(16)203.97%
Revenue beat(2)2
Avg Revenue beat(2)1.23%
Min Revenue beat(2)1.23%
Max Revenue beat(2)1.23%
Revenue beat(4)4
Avg Revenue beat(4)6.13%
Min Revenue beat(4)1.23%
Max Revenue beat(4)11.71%
Revenue beat(8)6
Avg Revenue beat(8)2.95%
Revenue beat(12)10
Avg Revenue beat(12)4.59%
Revenue beat(16)12
Avg Revenue beat(16)4.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)92.88%
EPS NQ rev (3m)-59.09%
EPS NY rev (1m)4.47%
EPS NY rev (3m)23.11%
Revenue NQ rev (1m)-10.13%
Revenue NQ rev (3m)-15%
Revenue NY rev (1m)-0.6%
Revenue NY rev (3m)-0.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.53 | ||
| Fwd PE | 13.48 | ||
| P/S | 0.94 | ||
| P/FCF | 5.06 | ||
| P/OCF | 5.04 | ||
| P/B | 2.14 | ||
| P/tB | 3.83 | ||
| EV/EBITDA | 2.31 |
EPS(TTM)0.98
EY22.07%
EPS(NY)0.33
Fwd EY7.42%
FCF(TTM)0.88
FCFY19.77%
OCF(TTM)0.88
OCFY19.83%
SpS4.73
BVpS2.08
TBVpS1.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.86% | ||
| ROE | 46.27% | ||
| ROCE | 39.77% | ||
| ROIC | 31.42% | ||
| ROICexc | 183.86% | ||
| ROICexgc | N/A | ||
| OM | 19.35% | ||
| PM (TTM) | 20.35% | ||
| GM | 72.33% | ||
| FCFM | 18.58% |
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
ROICexc(3y)84.91%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)22.75%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y271.17%
ROICexc growth 5YN/A
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
F-Score6
Asset Turnover1.22
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 1.01 | ||
| Debt/EBITDA | 0.19 | ||
| Cap/Depr | 1.04% | ||
| Cap/Sales | 0.05% | ||
| Interest Coverage | 5.43 | ||
| Cash Conversion | 77.32% | ||
| Profit Quality | 91.27% | ||
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.62 | ||
| Altman-Z | -5.53 |
F-Score6
WACC10.94%
ROIC/WACC2.87
Cap/Depr(3y)62.9%
Cap/Depr(5y)77.72%
Cap/Sales(3y)2.82%
Cap/Sales(5y)3.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)415.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%233.33%
EPS Next Y-17.31%
EPS Next 2Y-26.51%
EPS Next 3Y-17.16%
EPS Next 5Y-12.89%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%11.25%
Revenue Next Year-3.32%
Revenue Next 2Y-3.85%
Revenue Next 3Y-2.82%
Revenue Next 5Y-1.09%
EBIT growth 1Y135.74%
EBIT growth 3Y187.73%
EBIT growth 5YN/A
EBIT Next Year71.67%
EBIT Next 3Y11.16%
EBIT Next 5YN/A
FCF growth 1Y291%
FCF growth 3Y23.46%
FCF growth 5Y11.98%
OCF growth 1Y43.58%
OCF growth 3Y23.52%
OCF growth 5Y11.7%